| These data indicate that miR-27a contributes a tumor suppressor-like activity in acute leukemia cells via regulation of apoptosis | leukemia, |
| miR-27a suppresses tumorigenesis of esophageal squamous cell carcinoma by targeting KRAS. | esophageal, |
| Study has revealed miR-27a as a tumor suppressor and has identified SGPP1 and Smad2 as novel targets of miR-27a, linking to STAT3 for regulating cancer cell proliferation, apoptosis and migration in colorectal cancer. | colorectal, |
| miR-27a was shown to be a significant tumor suppressor by targeting and decreasing PHB protein expression in glioma U251 cells. miR-27a targeting of PHB may be a novel potential therapeutic strategy for glioma | glioma, |
| MicroRNA-27a functions as a tumor suppressor in renal cell carcinoma by targeting epidermal growth factor receptor | kidney, |
| Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression | prostate, |
| our results indicated that microRNA-27a-3p acts as a tumor suppressor in non-small lung cancer via targeting homeobox B8. | lung, |
| MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin | gastric, |
| MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. | gastric, |
| Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. | breast, |
| The [G] allele of rs895819, located in the terminal loop of pre-miR-27a oncogene, is associated with reduced familial breast cancer risk. | breast, |
| A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. | breast, |
| Data indicate that miR-27a plays an oncogenic role by targeting Spry2 and modulating the malignant, biological behavior of pancreatic cancer cells. | pancreatic, |
| miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. | pancreatic,colorectal, |
| Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer. | prostate, |
| Lentiviral expression of anti-microRNAs targeting miR-27a inhibits proliferation and invasiveness of U87 glioma cells. | glioma, |
| Oncogenic MicroRNA-27a is a target for genistein in ovarian cancer cells. | ovarian, |
| miR-27a is frequently up-regulated in hepatocellular carcinoma tissues and hepatocellular carcinoma cell lines. up-regulation of miR-27a may play an oncogenic role in the development of hepatocellular carcinoma | liver, |
| Data show that miR-27a is up-regulated in laryngeal squamous cell carcinoma and acts as an oncogene through down-regulation of PLK2. | laryngeal, |
| Results found that miR-27a was commonly overexpressed in gastric cancer and high expression of miR-27a was associated with distant metastasis, lymph node metastasis, advanced T stage and advanced clinical stage. These data suggest that miR-27a functions as a crucial oncogenic miRNA in gastric cancer. It can promote proliferation and metastasis of tumor cells by suppressing PHLPP2 and activating the AKT/GSK3beta pathway. | gastric, |